Institut of Molecular and Cellular Pharmacology, Laboratory of Excellence DistALZ, Université Côte d'Azur, INSERM, CNRS, Sophia-Antipolis, 06560, Valbonne, France.
Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Acta Neuropathol. 2021 Jan;141(1):39-65. doi: 10.1007/s00401-020-02234-7. Epub 2020 Oct 20.
Several lines of recent evidence indicate that the amyloid precursor protein-derived C-terminal fragments (APP-CTFs) could correspond to an etiological trigger of Alzheimer's disease (AD) pathology. Altered mitochondrial homeostasis is considered an early event in AD development. However, the specific contribution of APP-CTFs to mitochondrial structure, function, and mitophagy defects remains to be established. Here, we demonstrate in neuroblastoma SH-SY5Y cells expressing either APP Swedish mutations, or the β-secretase-derived APP-CTF fragment (C99) combined with β- and γ-secretase inhibition, that APP-CTFs accumulation independently of Aβ triggers excessive mitochondrial morphology alteration (i.e., size alteration and cristae disorganization) associated with enhanced mitochondrial reactive oxygen species production. APP-CTFs accumulation also elicit basal mitophagy failure illustrated by enhanced conversion of LC3, accumulation of LC3-I and/or LC3-II, non-degradation of SQSTM1/p62, inconsistent Parkin and PINK1 recruitment to mitochondria, enhanced levels of membrane and matrix mitochondrial proteins, and deficient fusion of mitochondria with lysosomes. We confirm the contribution of APP-CTFs accumulation to morphological mitochondria alteration and impaired basal mitophagy in vivo in young 3xTgAD transgenic mice treated with γ-secretase inhibitor as well as in adeno-associated-virus-C99 injected mice. Comparison of aged 2xTgAD and 3xTgAD mice indicates that, besides APP-CTFs, an additional contribution of Aβ to late-stage mitophagy activation occurs. Importantly, we report on mitochondrial accumulation of APP-CTFs in human post-mortem sporadic AD brains correlating with mitophagy failure molecular signature. Since defective mitochondria homeostasis plays a pivotal role in AD pathogenesis, targeting mitochondrial dysfunctions and/or mitophagy by counteracting early APP-CTFs accumulation may represent relevant therapeutic interventions in AD.
最近有几条证据表明,淀粉样前体蛋白衍生的 C 端片段(APP-CTFs)可能是阿尔茨海默病(AD)病理的一个病因触发因素。改变的线粒体动态平衡被认为是 AD 发展的早期事件。然而,APP-CTFs 对线粒体结构、功能和自噬缺陷的具体贡献仍有待确定。在这里,我们在表达 APP 瑞典突变的神经母细胞瘤 SH-SY5Y 细胞或与β-和γ-分泌酶抑制相结合的β-分泌酶衍生的 APP-CTF 片段(C99)的细胞中证明,APP-CTFs 的积累与 Aβ无关,会引发过度的线粒体形态改变(即大小改变和嵴结构紊乱),并伴随着增强的线粒体活性氧产生。APP-CTFs 的积累还会引发基础自噬失败,表现为 LC3 的增强转化、LC3-I 和/或 LC3-II 的积累、SQSTM1/p62 的非降解、Parkin 和 PINK1 向线粒体的募集不一致、膜和基质线粒体蛋白水平的增强,以及线粒体与溶酶体融合的缺陷。我们在接受 γ-分泌酶抑制剂治疗的年轻 3xTgAD 转基因小鼠以及注射腺相关病毒-C99 的小鼠体内证实了 APP-CTFs 积累对形态学改变和基础自噬受损的贡献。2xTgAD 和 3xTgAD 老年小鼠的比较表明,除了 APP-CTFs 之外,Aβ 对晚期自噬激活还有额外的贡献。重要的是,我们报告了人类散发性 AD 大脑中 APP-CTFs 的线粒体积累与自噬失败的分子特征相关。由于线粒体动态平衡的缺陷在 AD 的发病机制中起着关键作用,通过拮抗早期 APP-CTFs 的积累来靶向线粒体功能障碍和/或自噬可能是 AD 的相关治疗干预措施。